Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.

Suppr

超能文献

作者信息

Kiguchi Toru, Tauchi Tetsuzo, Ito Yoshikazu, Miyazawa Keisuke, Kimura Yukihiko, Ohyashiki Kazuma

出版信息

Leuk Res. 2009 Mar;33(3):506-8. doi: 10.1016/j.leukres.2008.04.018. Epub 2008 Jun 3.

DOI:10.1016/j.leukres.2008.04.018

PMID:18533259

Abstract

摘要

相似文献

Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.

Leuk Res. 2009 Mar;33(3):506-8. doi: 10.1016/j.leukres.2008.04.018. Epub 2008 Jun 3.

[Chronic myeloid leukemia and imatinib mesylate therapy].

Vnitr Lek. 2004 Jan;50(1):10-2.

Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.甲磺酸伊马替尼致慢性髓性白血病患者单核细胞减少后发生的单核细胞增生性李斯特菌脑膜炎

Clin Infect Dis. 2005 Dec 1;41(11):1684-5. doi: 10.1086/498031.

Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.

Haematologica. 2006 Jul;91(7):994-5.

[Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1660-2.

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.双费城染色体：甲磺酸伊马替尼治疗慢性粒细胞白血病的一个耐药因素。

Int J Lab Hematol. 2008 Aug;30(4):346-8. doi: 10.1111/j.1751-553X.2007.00957.x.

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.伊马替尼剂量递增以实现慢性期晚期慢性髓性白血病患者的分子反应。

Leuk Res. 2009 Jun;33(6):e17. doi: 10.1016/j.leukres.2008.10.015. Epub 2008 Nov 25.

Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.

Br J Haematol. 2008 Sep;142(6):992-5. doi: 10.1111/j.1365-2141.2008.07283.x. Epub 2008 Jun 28.

Prognostic variables in patients with chronic myeloid leukemia treated with imatinib.接受伊马替尼治疗的慢性髓性白血病患者的预后变量。

Haematologica. 2006 Feb;91(2):145a.

Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.甲磺酸伊马替尼治疗慢性期慢性粒细胞白血病时的持续性中性粒细胞减少症。

Am J Hematol. 2009 May;84(5):302-5. doi: 10.1002/ajh.21383.

引用本文的文献

Investigating adherence to tyrosine kinase inhibitors in renal cancer.研究肾癌患者对酪氨酸激酶抑制剂的依从性。

J Oncol Pharm Pract. 2024 Jun 5:10781552241259354. doi: 10.1177/10781552241259354.

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.酪氨酸激酶抑制剂治疗慢性髓性白血病的依从性对生存的影响。

Korean J Intern Med. 2021 Nov;36(6):1450-1458. doi: 10.3904/kjim.2021.158. Epub 2021 Nov 1.

Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.台湾慢性粒细胞白血病患者使用酪氨酸激酶抑制剂的副作用及药物依从性

Medicine (Baltimore). 2018 Jun;97(26):e11322. doi: 10.1097/MD.0000000000011322.

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.慢性髓性白血病中BCR-ABL抑制剂治疗依从性的测量：现状与未来挑战

Haematologica. 2014 Mar;99(3):437-47. doi: 10.3324/haematol.2012.082511.

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.患者咨询计划以提高慢性髓性白血病患者对伊马替尼的依从性。

Med Oncol. 2012 Jun;29(2):1179-85. doi: 10.1007/s12032-011-9926-8. Epub 2011 Apr 7.

Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.甲磺酸伊马替尼治疗儿童 CML 的疗效显著优于伊马替尼治疗前时代。

Int J Hematol. 2011 Feb;93(2):186-191. doi: 10.1007/s12185-010-0764-9. Epub 2011 Jan 14.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验